# Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

> **NCT04661384** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Ependymoma
- Glioblastoma
- Medulloblastoma
- Recurrent Metastatic Malignant Neoplasm in the Leptomeninges

## Interventions

- **BIOLOGICAL:** IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

## Key facts

- **NCT ID:** NCT04661384
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-05
- **Primary completion:** 2027-01-12
- **Final completion:** 2027-01-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661384, "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04661384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*